Pathologic stage I non-small cell lung cancer with high levels of preoperative serum carcinoembryonic antigen: Clinicopathologic characteristics and prognosis

Journal of Thoracic and Cardiovascular Surgery

Volumn 135, Issue 1, 2008, Pages 44-49

  Matsuguma, Haruhisa ^a   Nakahara, Rie ^a   Igarashi, Seiji ^a   Ishikawa, Yoshinori ^a,b   Suzuki, Haruko ^a,b   Miyazawa, Naoto ^a   Honjo, Satoshi ^a,c   Yokoi, Kohei ^a,b  

^a TOCHIGI CANCER CENTER   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Omuta National Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CIGARETTE SMOKING; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LYMPHATIC SYSTEM; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PLEURA; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; SEX DIFFERENCE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME;

EID: 37549027584     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2007.09.032     Document Type: Article

References (19)

1. Winton T., Livingston R., Johnson D., Rigas J., Johnston M., Butts C., et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352 (2005) 2589-2597
2. Arriagada R., Bergman B., Dunant A., Le Chevalier T., Pignon J.P., and Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350 (2004) 351-360
3. Douillard J.Y., Rosell R., De Lena M., Carpagnano F., Ramlau R., Gonzales-Larriba J.L., et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7 (2006) 719-727
4. Potti A., Mukherjee S., Petersen R., Dressman H.K., Bild A., Koontz J., et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 355 (2006) 570-580
5. Okada M., Nishio W., Sakamoto T., Uchino K., Yuki T., Nakagawa A., et al. Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer: analysis of 1,000 consecutive resections for clinical stage I disease. Ann Thorac Surg 78 (2004) 216-221
6. Sawabata N., Ohta M., Takeda S., Hirano H., Okumura Y., Asada H., et al. Serum carcinoembryonic antigen level in surgically resected clinical stage I patients with non-small cell lung cancer. Ann Thorac Surg 74 (2002) 174-179
7. Harpole Jr. D.H., Herndon II J.E., Wolfe W.G., Iglehart J.D., and Marks J.R. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 55 (1995) 51-56
8. Macchiarini P., Fontanini G., Hardin M.J., Chuanchieh H., Bigini D., Vignati S., et al. Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non-small-cell lung cancer. J Thorac Cardiovasc Surg 106 (1993) 80-89
9. Harpole Jr. D.H., Richards W.G., Herndon II J.E., and Sugarbaker D.J. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg 61 (1996) 1470-1476
10. Ichinose Y., Yano T., Asoh H., Yokoyama H., Yoshino I., and Katsuda Y. Prognostic factors obtained by a pathologic examination in completely resected non-small-cell lung cancer. An analysis in each pathologic stage. J Thorac Cardiovasc Surg 110 (1995) 601-605
11. Takamochi K., Nagai K., Suzuki K., Yoshida J., Ohde Y., and Nishiwaki Y. Clinical predictors of N2 disease in non-small cell lung cancer. Chest 117 (2000) 1577-1582
12. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 111 (1997) 1710-1717
13. World Health Organization. Histological Typing of Lung and Pleural Tumours. 3rd ed. (1999), World Health Organization, Geneva
14. Shimizu K., Yoshida J., Nagai K., Nishimura M., Ishii G., Morishita Y., et al. Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer. J Thorac Cardiovasc Surg 130 (2005) 160-165
15. Fujisawa T., Iizasa T., Saitoh Y., Sekine Y., Motohashi S., Yasukawa T., et al. Smoking before surgery predicts poor long-term survival in patients with stage I non-small-cell lung carcinomas. J Clin Oncol 17 (1999) 2086-2091
16. Okada M., Nishio W., Sakamoto T., Uchino K., Yuki T., Nakagawa A., et al. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma. Ann Thorac Surg 78 (2004) 1004-1010
17. Suzuki T., Sobue T., Fujimoto I., Doi O., and Tateishi R. Association of adenocarcinoma of the lung with cigarette smoking by grade of differentiation and subtype. Cancer Res 50 (1990) 444-447
18. Bae S.N., Namkoong S.E., Jung J.K., Kim C.J., Park J.S., Kim J.W., et al. Prognostic significance of pretreatment squamous cell carcinoma antigen and carcinoembryonic antigen in squamous cell carcinoma of the uterine cervix. Gynecol Oncol 64 (1997) 418-424
19. Kosugi S., Nishimaki T., Kanda T., Nakagawa S., Ohashi M., and Hatakeyama K. Clinical significance of serum carcinoembryonic antigen, carbohydrate antigen 19-9, and squamous cell carcinoma antigen levels in esophageal cancer patients. World J Surg 28 (2004) 680-685